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Abstract: 
Introduction: Breast cancer is the most common neoplasm in women and the second leading cause of cancer-
related mortality in females worldwide. Breast cancer is the second most common type of cancer (after lung cancer), 
and the fifth most common cause of cancer death.  
Objectives of the study: The main objective of the study is to assess the blood circulating serum biomarkers for the 
diagnosis of breast cancer.  
Methodology of the study: This cross sectional study was conducted at DHQ teaching hospital Sahiwal during 
February 2018 to November 2018. Breast cancer notifications were confirmed and characterized by postal 
questionnaire sent to treating clinicians (consultant, or General Practitioner if details not provided by the 
volunteer), which was designed to ascertain clinical and histological data on diagnosed cases (date of diagnosis, 
histology, nodal status, staging, grade, prognosis, ER, PR and HER2 status).   
Results: The results indicates that CTC, CEA and ALP are the best indicating serum biomarkers for the diagnosis 
and progression of breast cancer. Mean, median and SD shows that there is a significant relationship in these serum 
biomarkers.  
Conclusion: It is concluded that biomarkers are the useful tool for the analysis of progression of breast cancer in 
females. 
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INTRODUCTION: 
Breast cancer is the most common neoplasm in 
women and the second leading cause of cancer-
related mortality in females worldwide. Breast 
cancer is the second most common type of cancer 
(after lung cancer), and the fifth most common cause 
of cancer death. There is thus an urgent need for early 
biomarkers that could predict disease outcome, 
providing prognostic information to the clinician for 
treatment stratification [1]. The addition of a blood-
based tumor marker test may also increase patient 
compliance as blood testing is more acceptable and 
would also circumvent the problems associated with 
imaging high-density breast tissue [2]. Breast cancer, 
the most common cancer among women worldwide, 
accounts for the highest morbidity and mortality [3]. 
The etiology of breast cancer is multifactorial and 
numerous risk factors associated with breast cancer 
may exert their effects via generation of an oxidative 
stress status [4]. In all over the world, breast cancer is 
considered the most common type of cancer among 
women [5]. Every year, breast cancer accounts for 
22% of new cancers found in women. Breast cancer is 
a disease with multiple etiological factors linked to 
genetic, environmental, social demographic, 
behavioral, psychological and hormonal factors6. 
Tumor heterogeneity that enables malignant 
progression by evolutionary selection is also the major 
cause of emergent resistance during cancer treatment 
[4]. Yet, we rely on few standard diagnostic tumor 
biopsies for the characterization of a given cancer. 
These specimens will provide only a partial 
characterization of the overall makeup of the dynamic 
systemic disease cancer represents with intratumoral 
and interlesional heterogeneity as well as emerging 
host responses [7].  
 
Objectives of the study 
The main objective of the study is to assess the blood 
circulating serum biomarkers for the diagnosis of 
breast cancer. 
 
METHODOLOGY OF THE STUDY: 
This cross sectional study was conducted at DHQ 
teaching hospital Sahiwal during February 2018 to 
November 2018. Breast cancer notifications were 
confirmed and characterized by postal questionnaire 
sent to treating clinicians (consultant, or General 
Practitioner if details not provided by the volunteer), 
which was designed to ascertain clinical and 
histological data on diagnosed cases (date of 
diagnosis, histology, nodal status, staging, grade, 
prognosis, ER, PR and HER2 status). The main 
eligibility requirements for this study included the 
patient's written informed consent, metastatic breast 
cancer, patients entering first-line chemotherapy 
(chosen by clinicians) with or without targeted 
therapy, life expectancy of at least three months, and 
measurable or evaluable disease.  
 
Statistical analysis 
The data were analyzed using one-way analysis of 
variance (ANOVA) followed by multiple comparison 
test. All biochemical experiments were performed 
thrice in triplicates to ensure reproducibility. 
 
RESULTS: 
The results indicates that CTC, CEA and ALP are the 
best indicating serum biomarkers for the diagnosis and 
progression of breast cancer. Mean, median and SD 
shows that there is a significant relationship in these 
serum biomarkers. CTC and serum marker values at 
inclusion repartition in percentile, mean, median range 
are given in Table 1. 
 
Table 01: Serum marker values repartition at inclusion 
  Mean SD Quantile 
0% 
Quantile 
25% 
N 
CEA 7.20 18.23 0.04 0.4 212 
CYFRA21 9.01 29.51 0.1 0.65 191 
LDH 1.39 2.02 0.28 0.71 220 
ALP 1.056 1.00 0.26 0.58 241 
CTC and serum markers values at inclusion repartition in percentile, mean, median range. Values for serum marker 
are expressed in ULNV, upper limit of the normal value. 
DISCUSSION: 
Here, by comparing the early and late changes of five 
blood markers together with CTC changes for PFS 
prediction, we showed no clear superiority of CTC 
over the other serum markers [8]. This result was, 
however, not the primary endpoint of our study, and 
the statistical power of these analyses may still be 
discussed, although performed in more than 200 
patients [9].  
Predictive biomarkers that can guide treatment 
decision have been sought after to identify subsets of 
patients who would be “exceptional responders” to 
specific cancer therapies, or individuals who would 
benefit from alternative treatment modalities [10]. An 
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example of ctDNA as a potential predictive biomarker 
is the measurement of O6-methyl-guanine-methyl-
transferase (MGMT) promoter methylation from 
ctDNA in glioblastoma multiforme (GBM) patients. 
This would determine potential benefits from adjuvant 
alkylating chemotherapy such as temozolomide or 
dacarbazine, in addition to standard post-operative 
adjuvant radiation [11]. 
CONCLUSION: 
It is concluded that biomarkers and TAC are the useful 
tool for the analysis of progression of breast cancer in 
females. 
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